Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3788510 | 0.90 | LMNA (0.48) | LMNACYP3A4ADORA2AACHEMAPT | |
| SCHEMBL363290 | 0.89 | CYP3A4 (0.63) | LMNACYP3A4ADORA2AACHEALDH1A1 | |
| SCHEMBL3781402 | 0.88 | LMNA (0.56) | LMNACYP3A4ADORA2AACHEMAPT | |
| SCHEMBL3783548 | 0.88 | LMNA (0.65) | LMNACYP3A4MAPTTDP1GAA | |
| SCHEMBL28032593 | 0.87 | LMNA (0.66) | LMNACYP3A4ADORA2AACHEMAPT | |
| SCHEMBL27503998 | 0.85 | MKNK1 (0.47) | LMNACYP3A4ADORA2AMAPTTDP1 | |
| SCHEMBL4446422 | 0.84 | MAPT (0.67) | LMNACYP3A4ACHEMAPTTDP1 | |
| SCHEMBL3787833 | 0.83 | GAPDH (0.46) | LMNACYP3A4ADORA2AACHEMAPT | |
| SCHEMBL3787458 | 0.83 | BACE1 (0.48) | LMNACYP3A4ADORA2AACHEMAPT | |
| SCHEMBL4607313 | 0.82 | LMNA (0.71) | LMNACYP3A4ACHEMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LMNA 3250/4885CYP3A4 177/4885ADORA2A 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.